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Objective: To investigate warning effect of serum miRNA for intracranial aneurysm rupture through microarray
hybridization.
Methods: 24 were selected from 560 patients in our department and divided into group A, B, C and D. They are
aneurysms with daughter aneurysms group, aneurysm without daughter aneurysms group, ruptured aneurysms
group and angiography negative group. Then a microarray study was carried out using serum miRNA. Differentially
expressed miRNAs were identified. Cluster analysis was performed in order to make the results looks more intuitive
and potential gene targets were retrieved from miRNA target prediction databases.
Results: Microarray study identified 86 miRNAs with significantly different (p < 0.05) expression levels between three
experimental groups and control group. Among them 69 are up-regulated and 17 are down-regulated. All miRNAs
in group A are up-regulated, while there are up and down-regulated in group B and C. A total of 8291 predicted
target genes are related to these miRNAs. Bioinformatic analysis revealed that several target genes are involved in
apoptosis and activation of cells associated with function of vascular wall.
Conclusion: Our gene level approach reveals several different serum miRNAs between normal people and
aneurysm patients, as well as among different phases of aneurysm, suggesting that miRNA may participate in the
regulation of the occurrence and development of intracranial aneurysm, and also have warning effect for
intracranial aneurysm rupture. All differently expressed miRNA in group A are up-regulated, which may suggesting
protective function of miRNA for intracranial vascular wall.
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Intracranial aneurysm is one of the leading causes of
subarachnoid hemorrhage; however the pathogenesis of
aneurysm is not clear. Studies show that hemodynamic,
gene, infection, ageing and congenital factors may relate
to its occurrence and development. Diagnosis of intra-
cranial aneurysm is mainly depends on imaging diag-
nostic methods, such as CT, CTA and DSA (golden
standard). Just like aneurysms of other body parts, intra-
cranial aneurysm is characterized by the apoptosis of
smooth muscle cells, degradation of the extracellular* Correspondence: jxy200321@gmail.com; liyouxiang@263.net
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reproduction in any medium, provided the ormatrix, potent inflammatory response, and increased
oxidative stress in the aortic wall. Infiltration by inflam-
matory cells may act as mediators which lead to apop-
tosis of vascular smooth muscle cells [1]. However,
molecular mechanism of intracranial aneurysm is still
unknown.
MiRNA is a novel class of small, non-coding, single-
stranded RNA that negatively regulates gene expression
via translational inhibition or mRNA degradation fol-
lowed by protein synthesis repression. MiRNA regulates
approximately 30% of the encoding genes of the human
genome at the posttranscriptional level by incorporating
into the RNA induced silencing complex (RISC) and pref-
erentially binding to the 3’ untranslated region (3’UTR) of
target mRNA. RISC then inhibits gene expression eitherThis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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thousands of target genes that are regulated by miRNA [3],
many belong to biological pathways including immune re-
sponse and apoptosis [4]. Tissue-specific and phase-specific
expression is an important characteristic of miRNA expres-
sion [5]. Such different expression levels in different tissues
suggest that the physiological functions of miRNA in differ-
ent tissues may be different [6]. miRNA can be detected in
serum in a remarkably stable form [7] and can withstand
repetitive freezing and thawing cycles [7,8], making them
attractive biomarkers for human diseases.
Daughter aneurysms, also known as daughter blebs,
are focal bulges that are commonly found on the surface
of original aneurysm walls [9]. It is considered high risk
factor for the aneurysm rupture. Crompton performed a
pathological study and found that 57% of ruptured intra-
cranial aneurysms had daughter ‘bubbles’, whereas the
bubbles were only found in 16% of un-ruptured aneu-
rysms [10]. In order to study the relationship between
serum miRNA and the occurrence and development of
intracranial aneurysm, we initially analyzed circulating
miRNA expression differences of the four characterized
groups through microarray hybridization technology.
This undoubtedly laid a solid foundation for further
research of warning effect of circulating miRNA for intra-
cranial aneurysm‘s occurrence, development and rupture.
Method
Sample acquisition
We selected 24 out of 560 patients that went to neuro-
intervention department in our hospital from December
2011 to May 2012. As is illustrated in Figure 1, 216 patients
are screening out based on certain criteria (history of cere-
brovascular disease like stenosis, occlusion; history of other
circulatory system diseases like hypertension, hyperlipid-
emia, coronary heart disease, etc.; history of blood system
inflammation disease; history of diabetes and tumor; age of
patients greater than 80 or less than 20 years old; largest
diameter of aneurysm more than 25 mm or less than
3.0 mm). Besides, considering more precise indicators of
daughter aneurysm, we selected 10 (male = 3 female = 7)
from 17 patients with typical blebs and ignored patients
with possible controversial cystic protrusions on aneu-
rysms. Finally, in order to make our screening criteria
much striker, we enrolled the above mentioned 3 males
with typical blebs. Then we selected 3 from 7 females of
similar age in the same group and logically selected 3 males
and 3 females on the same basis respectively from other
three groups. We categorized these 24 patients into 4
groups. A is aneurysms with daughter aneurysms group.
B is aneurysm without bleb group. C is the group of
ruptured aneurysms that could be proved by subarach-
noid hemorrhage of CT and D is angiography negative
(no hemorrhage and no aneurysm) group. Each groupwas consist of 3 males and 3 females, and their age
ranged from 24 to 78 years old (Average age = 39.7).
The size of aneurysms ranged from 20 × 15 mm to 2.5 ×
1.5 mm (Average size = 4.5 × 3.5 mm). There were no
statistical differences (p < 0.05) among 4 groups in both
the age of the patients and the size of aneurysms. In
addition, 24 patients all had no history of cerebrovascular
disease, circulatory system diseases (hypertension, hy-
perlipidemia, coronary heart disease, etc.), blood system
inflammation diseases, diabetes or tumor. Aneurysms of
these 18 patients mainly located in ophthalmic artery
(n = 7, 38.9%), basilar artery (n = 5, 27.8%), posterior
communicating artery (n = 3, 16.7%) and internal ca-
rotid artery (n = 3, 16.7%). The control group patients
are angiography negative (no hemorrhage and no
aneurysm). Since the hospital is the largest neurosur-
gery center in china, most of the patients here were
referred by local doctors with consideration of operat-
ing difficulty and limited skill level. This lead to distri-
bution difference of aneurysms compared with data
reported in literatures.
The protocol of this study was carried out according to
the principles of the Declaration of Helsinki and approved
by the Medical Ethics Committee in Beijing Tiantan
Hospital. Written informed consent was obtained from all
the participants before enrolment.
MicroRNA isolation
Blood samples of 24 subjects were taken under the condi-
tion of resting and fasting state in the morning, no intra-
venous transfusion or drug interference. Peripheral blood
samples (2 ml) were collected into EDTA-containing
tubes. Whole blood was centrifuged at 1200 g for 15 min
at room temperature within 30 min after blood collection,
and the supernatant was transferred into microcentrifuge
tubes, followed by a second centrifugation at 12000 g for
10 min at 48°C to remove cellular debris. Plasma was then
aliquoted and stored at −75°C until use. Hemosiderin
absence could prove that miRNA in the serum was not
released from broken red blood cells. Total RNA was ex-
tracted from plasma using the mirVana TM RNA Isolation
Kit (Applied Biosystems, Foster City, CA, USA) according
to the manufacturer’s specifications. Quality of the RNA
samples was assessed by Nano Drop 2000 spectrophotom-
eter (Thermo technologies). Then take 100 nanogram of
the miRNA and add to a constant volume of 2 μm with
nuclease-free water for hybridization.
Microarray study
Total RNAs was labeled with the microRNA Complete
Labeling and Hyb Kit (Agilent, USA) and hybridized on
the Human microRNA Microarray Kit (Release 16.0,
Agilent), which contains 60 000 probes for 1205 human
and 144 human viral microRNAs. Hybridization signals
Figure 1 Diagram of sample acquisition. As revealed in this figure, 216 patients are selected from a total number of 560 under series of
criterions. And then we divided them into 4 groups according to state of aneurysms. They are Aneurysm with daughter aneurysms group,
aneurysm without bleb group, ruptured aneurysms group and angiography negative group. 3 males and 3 females are selected randomly from
each group to form group A, B, C and D respectively.
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lent) and the scanned images were analyzed using Agilent
Feature Extraction Software (Agilent). Gene spring 12.0
was used to shift percentile normalization and principal
component analyzed (PCA) analysis. At last, cluster ana-
lysis was carried out with Cluster 3.0 and differentially
expressed miRNA was screened out.
Bioinformatic analyses
The miRNA target prediction databases TargetScan was
used to predict target genes related to these significant
miRNAs. Functional classification of the target genes
was carried out with Gene Ontology (GO) analysis with
using Web Gestalt to create a hierarchy of the GO anno-
tations of the predicted targets.
Results
PCA analysis and cluster analysis results
Gene Spring 12.0 was used to have result processed
standardized, as well as principal component analyzed.Figure 2 is the results of the analysis of PCA. After the
removal of secondary factor that has no statistical sig-
nificance (p > 0.05), major elements (components 1 and
2) were used as standards of making new parameters. As
what is illustrated in Figure 2, X-axis and Y-axis respect-
ively stand for component 1 and 2. Small squares of the
same color represent patients from the same group and
have similar proportions in two components. From the
distribution of small squares, we could conclude that
miRNA expression is different among different groups.
We have the normalized data cluster analyzed with
Cluster 3.0, and some of the result is in Figure 3. We sim-
ply cited 4 differential expression result of miRNA under
different selection criteria. (a), (b), (c) and (d) respectively
stands for differential expression results of miRNA: A vs
control group, B vs control group, C vs control group and
A+B+C vs control group. Take a as an example, C1-6 in
are 6 patients of control group and 197S, 212S 243S, 161S
and 107S represent 6 patients of group A. Red stands for
up-regulated and green stands for down-regulated. As is
Figure 2 Results of the analysis of PCA. Red: aneurysms with daughter aneurysms group; Blue: aneurysm without bleb group; Dark: ruptured
aneurysms group; Gray: angiography negative group. X-axis and Y-axis respectively stand for component 1 and 2. Small squares of the same color
represent patients from the same group and have similar proportions in two components. The distribution of small squares illustrates that miRNA
expression levels are different between different teams.
Jin et al. Journal of Translational Medicine 2013, 11:296 Page 4 of 9
http://www.translational-medicine.com/content/11/1/296revealed in the figure, miRNA expression levels are obvi-
ously different among different groups.
Differentially expressed miRNA
Screening condition is FC > =2 and p < 0.05. What’s
more, at least 50% sample should be detected in the sta-
tistics that are compared. All data were processed using
GraphPad Prism 5.0 (GraphPad, San Diego, CA) and
SPSS software, version 17.0 (SPSS Inc, Chicago, IL).
Table 1 is the result of miRNA expression levels
between intracranial aneurysms of different phases and
normal people. As revealed, 86 out of all the miRNAs
probes have significantly different expression level. Com-
pared to the control group, 68 miRNA are up-regulated
and none is down-regulated in team A, 4 (hsa-miR-21,
hsa-miR-22, hsa-miR-3665, hsa-miR-720) are up-regulated
and 9 down-regulated in team B, 2 (hsa-miR-3679-5p,
hsa-miR-199a-5p) are up-regulated and 13 are down-
regulated in team C (Table 1). MiRNA-21, miRNA-22 and
miRNA-3665 are up-regulated in both A and B. MiRNA-
3679-5p is up-regulated in both A and C. Hsa-miR-1471,
hsa-miR-3945, hsa-miR-4253, hsa-miR-4314 and hsa-
miR-574-5p are down-regulated in both B and C.
Bioinformatic analyses
A total number of 8291 predicted miRNA target genes
were related to these miRNAs.
And the pathways between DNA, protein and miRNA
are very complicated. Every miRNA is involved in theregulation of multiple pathways and the number ranges
from a few to hundreds. In the same way, one pathway
is regulated by several miRNAs. This indicates that each
miRNA has different biological effects in different
tissues. From the perspective of gene expression process,
these miRNAs are involved in the process of transcrip-
tion, post-transcription modification, translation and
post-translation modification; From the view of bio-
logical effects, they are involved in biological molecular
activation, transportation of molecular pathways, as well
as cell proliferation, differentiation and apoptosis. Con-
sidering possible factors such as aneurysm formation,
development and rupture, researchers selected some of
the miRNAs that related to myosin generation, vascular
endothelial growth and vascular smooth muscle cell
apoptosis. For example, hsa-miR-22 regulates smooth
muscle cell proliferation and transcription factor activity
negatively. Hsa-miR-21 induces apoptosis by extracellu-
lar signals. Hsa-miR-720 is involved in actin cytoskeleton
organization and biogenesis (Table 2).
Discussions
The pathogenesis of aneurysm may be related to heredity,
infection, hypertension, congenital factors, aging, etc.
Functional in vitro studies have shown that miRNA is
critical for endothelial cell gene expression and function.
It is estimated that more than 1,000 different miRNAs
exist in humans, and many are expressed in a tissue- and/
or cell-specific manner [11,12]. Their expression patterns
Figure 3 (See legend on next page.)
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Figure 3 Result of cluster analyses. (a), (b), (c) and (d) respectively stands for differential expression results of miRNA: A vs control group, B vs
control group, C vs control group and A+B+C vs control group. Red stands for up-regulated and green stands for down-regulated. C1-C6 stands
for patients of control group. 197S, 212S, 243S, 161S, 1S and 107S stand for 6 patients in Group A. 16S, 52S, 258S, 74S, 71S and 89S stand for 6
patients in Group B. 115S, 152S, 235S, 57S, 99S and 14S stand for 6 patients in group C. As is revealed in the figure, miRNA expression levels are
obviously different between different groups.
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And interestingly, miRNA can be detected in serum or in
plasma in a remarkably stable form. Circulating miRNAs
can withstand repetitive freezing and thawing cycles,
making them attractive as potential biomarkers for diverse
human diseases [7,8]. An ideal biomarker should be repro-
ducibly measurable with high sensitivity and specificity for
the clinical outcome of interest and should reflect an
important pathogenetic process. Circulating miRNAs are
exciting as potential biomarkers because they fulfill many
of these criteria. The origins or sources of circulating
miRNA are largely unknown. Some hypotheses have pro-
posed that they are secreted in membrane-bounded-
vesicles (apoptotic bodies, microvesicles, exosomes, etc.
[13]), while others stated that they are produced by-
products of dead cells [14]. Most of previous study of
miRNA in bioscience extracted miRNA from cell of tissue,
while the author and his partners investigated briefly the
relationship between serum miRNA and intracranial
aneurysm initially.
We reviewed some of current knowledge about the
role of miRNA in endothelial cells with emphasis on the
regulation of cellular senescence, angiogenesis, and
vascular inflammation. Plasma miRNA-208a seems to
be an ideal biomarker of AMI [15]. Mian Wang et al.
proved that microRNA-21 regulates vascular smooth
muscle cell function via targeting tropomyosin in
arteriosclerosis obliterans of lower extremities [16].
Hsa-miRNA-566 is related to inflammatory immune
responses of circulation system [17]; MiRNA-99b to
TGF-β-mediated cell extracellular matrix [18] and hsa-
miR-1180 to cell apoptosis [19]. Existing researches
have shown that the expression level of miRNAs (miR-
133a, miR-133b, miR-146a, miR-181a*, miR-204, miR-
21, miR-30c-2*, miR-331-3p) between aortic aneurysm
patients and normal person are statistically different
[20,21]. And their expression difference between intra-
cranial aneurysm patients and normal people are still
unknown. The formation of aneurysm can be a result of
multiple causes. When internal and external factors act
on artery wall, miRNA expression level changes to regu-
late target genes to cope with the stimulations. As a
result, original balance was destroyed, protein and
extracellular matrix was produced abnormally. All this
caused structural changes in arterial wall and the forma-
tion of aneurysm. In return, all the artery wall changesaffect the expression level of miRNA. This supposition is
also the theoretical foundation of our study.
We screen out 86 differentially expressed miRNAs,
among which miRNA21 regulates vascular smooth muscle
cell function via targeting tropomyosin [16]. Different
group represent different phase of aneurysm. 68 miRNA
are up-regulated and none is down-regulated in team A; 4
are up-regulated and 9 down-regulated in team B; 2 are
up-regulated and 13 are down-regulated in team C. So it
is plausible to hypothesize that aneurysm initiation,
growth and rupture have different molecular mechanisms
and further study needs to be done to find the variation
trend. MiRNA-21, miRNA-22 miRNA-720 and miRNA-
3665 are up-regulated in both A and B. MiRNA-3679-5p
is up-regulated in both A and C. Hsa-miR-1471, hsa-miR-
3945, hsa-miR-4253, hsa-miR-4314 and hsa-miR-574-5p
are down-regulated in both B and C. These miRNAs may
play more important role in the regulation of aneurysm
formation and development.
Aneurysm blebs have been identified as a risk factor for
increased risk for future rupture [22,23]. The presence of
multiple lobes or a daughter sac is more common in pre-
viously ruptured aneurysms compare to un-ruptured an-
eurysms [24]. Tsukahara reported a global rupture rate of
3.42% per year and a rupture rate of 28.3% per year in
aneurysms that contained blebs [22]. Therefore, to some
extent, we could define group A as high rupture risk
group. Differentially expressed miRNAs in group A are all
up-regulated, among which many participated in the activ-
ity of vascular smooth muscle, blood vascular endothelium
and growth factor, etc. For example, hsa-miR-106b, hsa-
miR-22 and hsa-miR-498 regulated vascular endothelial
growth factor receptor activity; hsa-miR-671 positively
regulates proliferation of smooth muscle cells. This may
imply protective function of these miRNA for intracranial
aneurysm rupture.
Over 700 miRNAs have been identified in the human
genome, of which 20% to 30% regulate human protein
coding genes [2]. A total number of 8291 predicted
miRNA target genes were related to these 86 miRNAs.
GO analysis revealed the function of these genes. In
Table 2, we listed 9 of the miRNAs (p < 0.01), target
genes and corresponding proteins that may be related
to the formation and development of intracranial
aneurysm. As revealed, hsa-miR-22 may negatively re-
gulate smooth muscle cell proliferation through TRIB1;
Table 1 86 differentially expressed miRNA (p < 0.05) R:
regulation of miRNA (↑ up-regulated; ↓ down-regulated
and -no difference)
miRNA A/control B/control C/control
R P FC R P FC R P FC
1 hsa-miR-584 ↑ 0.000 2.2
2 hsa-miR-301a ↑ 0.001 2.2 - -
3 hsa-miR-3679-5p ↑ 0.002 18.8 - -
4 hsa-miR-575 ↑ 0.003 18.9 - -
5 hsa-miR-671-5p ↑ 0.003 16.1 - -
6 hsa-miR-22 ↑ 0.003 11.8 - -
7 hsa-miR-720 ↑ 0.003 23.4 - -
8 hsa-miR-1915 ↑ 0.004 11.1 - -
9 hsa-miR-3665 ↑ 0.004 11.6 - -
10 hsa-miR-939 ↑ 0.004 14.7 - -
11 hsa-miR-3915 ↑ 0.005 14.4 - -
12 hsa-miR-630 ↑ 0.005 14.8 - -
13 hsa-miR-320d ↑ 0.005 14.4 - -
14 hsv2-miR-H10 ↑ 0.005 11.3 - -
15 hsa-miR-3656 ↑ 0.005 11.8 - -
16 hsa-miR-320e ↑ 0.005 14.3 - -
17 hsa-miR-1207-5p ↑ 0.005 12.8 - -
18 hsa-miR-125b-1* ↑ 0.005 44.9 - -
19 hsa-miR-486-5p ↑ 0.005 16.8 -
20 hsa-miR-498 ↑ 0.005 14.7 -
21 kshv-miR-K12-3 ↑ 0.006 10.6 - -
22 hsa-miR-4270 ↑ 0.006 12.0 - -
23 hsa-miR-30d ↑ 0.007 14.4 - -
24 hsa-miR-24 ↑ 0.006 7.93 - -
25 hsa-miR-1202 ↑ 0.007 12.1 - -
26 hsa-miR-4281 ↑ 0.007 10.9 - -
27 hsa-miR-638 ↑ 0.007 10.2 - -
28 hsa-miR-2861 ↑ 0.007 10.0 - -
29 hsa-miR-494 ↑ 0.007 24.8 - -
30 hsa-miR-134 ↑ 0.007 11.2 - -
31 hsa-miR-3162 ↑ 0.007 13.3 - -
32 hsa-miR-4298 ↑ 0.007 13.0 - -
33 hsa-miR-3663-3p ↑ 0.008 11.3 - -
34 hsa-miR-92a ↑ 0.008 12.4 - -
35 hsa-miR-4271 ↑ 0.008 13.2 - -
36 hsa-miR-106b ↑ 0.008 10.6 -
37 hsa-miR-21 ↑ 0.009 7.4 - ↑
38 hsa-miR-3141 ↑ 0.009 11.5 - -
39 hsa-miR-125a-3p ↑ 0.009 14.0 - -
40 hsa-miR-4306 ↑ 0.010 9.2 - -
41 hsa-miR-1225-5p ↑ 0.010 10.2 - -
Table 1 86 differentially expressed miRNA (p < 0.05) R:
regulation of miRNA (↑ up-regulated; ↓ down-regulated
and -no difference) (Continued)
42 hsa-miR-423-5p ↑ 0.010 11.9 - -
43 hsa-miR-197 ↑ 0.011 7.52 - -
44 hsa-miR-1268 ↑ 0.011 9.9 - -
45 hsv2-miR-H25 ↑ 0.012 7.7 - -
46 hsv2-miR-H24 ↑ 0.013 11.9 - -
47 hsa-miR-25 ↑ 0.013 6.8 - -
48 hsa-miR-93 ↑ 0.014 8.1 - -
49 hsa-miR-765 ↑ 0.014 13.5 - -
50 hsv2-miR-H6 ↑ 0.015 9.0 - -
51 hsa-miR-940 ↑ 0.016 14.0 - -
52 hsa-let-7d* ↑ 0.016 8.4 - -
53 hsa-miR-19b ↑ 0.017 5.1 - -
54 hsa-miR-483-5p ↑ 0.018 10.1 - -
55 hsa-let-7i ↑ 0.017 8.3 -
56 hsa-miR-4327 ↑ 0.019 11.2 - -
57 hsv1-miR-H17 ↑ 0.019 6.8 - -
58 hsa-miR-1275 ↑ 0.021 9.5 - -
59 hsa-let-7b ↑ 0.022 10.0 - -
60 hsa-miR-15b ↑ 0.023 5.3 - -
61 hsa-miR-320c ↑ 0.023 8.3 - -
62 hsa-miR-144 ↑ 0.025 8.0 - -
63 hsa-miR-762 ↑ 0.027 7.4 - -
64 hsa-miR-223 ↑ 0.030 4.4 - -
65 hsa-miR-3663-5p ↑ 0.042 9.3 - -
66 hsa-miR-151-3p ↑ 0.043 7.0 - -
67 hsa-miR-601 ↑ 0.045 7.2 - -
68 hsv1-miR-H6-5p ↑ 0.045 5.8 - -
69 hsa-miR-1471 - ↓ 0.000 25.9 -
70 hsa-miR-3945 - ↓ 0.002 14.2 -
71 hsa-miR-574-5p - ↓ 0.004 16.5
72 hsa-miR-4314 - ↓ 0.004 14.5 -
73 hsa-miR-1914* - ↓ 0.008 13.0 -
74 hsa-miR-30c-2* - ↓ 0.010 8.3
75 hsa-miR-22 - ↑ 0.022 3.1
76 hsa-miR-720 - ↑ 0.027 4.3
77 hsa-miR-1182 - ↓ 0.028 6.3
78 hsa-miR-4253 - ↓ 0.029 6.7
79 hsa-miR-3665 - ↑ 0.034 2.6
80 hsa-miR-1226* - ↓ 0.034 6.7
81 hsa-miR-21 - ↑ 0.039 2.1
82 hsa-miR-3945 - - ↓ 0.002 14.7
83 hsa-miR-4314 - - ↓ 0.003 14.9
84 hsa-miR-365 - - ↓ 0.003 12.6
Jin et al. Journal of Translational Medicine 2013, 11:296 Page 7 of 9
http://www.translational-medicine.com/content/11/1/296
Table 1 86 differentially expressed miRNA (p < 0.05) R:
regulation of miRNA (↑ up-regulated; ↓ down-regulated
and -no difference) (Continued)
85 ebv-miR-BART13 - - ↓ 0.004 12.8
86 hsa-miR-4253 - - ↓ 0.005 11.6
87 hsa-miR-936 - - ↓ 0.008 12.5
88 hsa-miR-574-5p - - ↓ 0.014 9.9
89 hsa-miR-1471 - - ↓ 0.019 9.0
90 hsa-miR-187* - - ↓ 0.032 7.5
91 hsa-miR-548q - - ↓ 0.038 7.0
92 hsa-miR-3194 - - ↓ 0.040 7.9
93 hsa-miR-371-5p - - ↓ 0.045 5.8
94 kshv-miR-K12-7* - - ↓ 0.046 8.7
95 hsa-miR-199a-5p - - ↑ 0.046 3.8
96 hsa-miR-3679-5p - - ↑ 0.048 3.3
P: Significant P value, the smaller P is, the bigger the difference will be. FC:
Absolute value of difference between groups. As is revealed, 86 out of all the
miRNAs probes have significantly different expression level. Compared with
control group, 68 miRNA are up-regulated and none is down-regulated in
team A, 4 are up-regulated and 9 down-regulated in team B, 2 are up-regulated
and 13 are down-regulated in team C.
*means low expression. It is a symbol based on naming rule of miRNA.
Table 2 9 of the target genes that may be related to the
formation, development and rupture of aneurysm
miRNA Symbol GO description
N R





↑ SSX3 Positive regulation of smooth muscle cell
proliferation/vascular endothelial growth
factor receptor signaling pathway
hsa-miR-720 ↑ ARFIP2 Actin cytoskeleton organization and
biogenesis
hsa-miR-365 ↓ BCL6B Negative regulation of transcription from
RNA polymerase II promoter
hsa-miR-498 ↑ EP300 Positive regulation of transcription factor
activity/positive regulation of transcription
from RNA polymerase II promoter
hsa-miR-574 ↓ EDN1 Positive regulation of smooth muscle cell
proliferation/blood vessel morphogenesis
hsa-miR-106b ↑ CHAF1A Vascular endothelial growth factor receptor
activity/vascular endothelial growth factor
receptor signaling pathway
hsa-miR-21 ↑ PDCD6 Induction of apoptosis by extracellular signals
hsa-miR-936 ↓ FMN2 Actin cytoskeleton organization and
biogenesis/actin binding
N: Name of miRNA; R: Regulation of miRNA(↑up-regulated and ↓down-regulated)
P: Significant P value, the smaller P is, the bigger the difference will be. Symbol:
Name abbreviation of the regulated gene; GO description: Brief introduction of
the protein translated from the gene.
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muscle cell proliferation and blood vessel morphogen-
esis through EDN1; hsa-miR-21 could induce of cell
apoptosis by using extracellular signals. Hsa-miR-720,
hsa-miR-365, hsa-miR-936 respectively has important
regulatory mechanism. Mutual interactions among these
genes and proteins may be the real causes of aneurysm
occurrence, development and rupture.
Our study had several limitations. Due to small sample
size and some other factors such as individual differ-
ences, there is a certain degree of bias. For example, the
distribution of points in principle components analysis
result reveals obvious bias. The classification of high risk
rupture group (aneurysms with daughter aneurysms
group) is lack of literature basis and specific criteria. In
addition, result of the experiment was not validated with
RT-PCR and we will next do this following work. Much
effort is needed before miRNA could be used as bio-
markers for the diagnosis of intracranial aneurysm rupture.
Conclusions
This study is initial exploration of the relationship be-
tween different phases of intracranial aneurysm by using
microarray hybridization. Our gene level approach re-
veals several different serum miRNAs between normal
people and aneurysm patients, as well as among differ-
ent phases of aneurysm, suggesting that miRNA may
participate in the regulation of the occurrence and
development of intracranial aneurysm, and also have
warning effect for intracranial aneurysm rupture. Up
regulation of all miRNAs in group A suggest protective
function for vascular wall. While more specific func-
tions, the relationship among the 86 miRNAs and their
connection with target genes require much efforts before
miRNA expression analysis was used in the clinical diag-
nosis and treatment of intracranial aneurysm.
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